Meet Me at the Microscope at USCAP 2020 - Insights
Mayo Clinic pathologists, researchers, and a wide spectrum of allied health staff will be in Los Angeles, California, for the 109th United States and Canadian Academy of Pathology Meeting (USCAP). Visit us at booth #716 on March 2 - 4, 2020...
Christmas and New Year's specimen shipment alert - Insights
Due to the Christmas and New Year's holiday's (recognized on Sunday, December 25th, and Sunday, January 1st ), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered. To ensure that your specimen vitality and...
Thanksgiving Holiday Shipment Schedules - Insights
The United States will observe the Thanksgiving holiday on Thursday, Nov. 23. On this day, Mayo Clinic Laboratories will be open; however, specimen shipments and deliveries to our laboratories will not be made by the carriers. To safeguard...
P.A.C.E./Florida Implementation of new analyzers and replacement of automation equipment in the Central Clinical Laboratory at Mayo Clinic in Rochester, Minnesota, prompted the laboratory to reassess blood collection volumes for commonly...
Alzheimer's Disease 2024: The Role of Biomarkers - Insights
PACE/State of FL This webinar, with expert presenters having both extensive lab and clinical experience, will discuss the latest updates in Alzheimer’s disease diagnostic criteria as well as a comprehensive review of the laboratory testing...
State-of-the-art genetics panel optimizes kidney disease treatment - Insights
Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC, explain how Mayo Clinic Laboratories renal genetics testing provides comprehensive, accurate and actionable results. Identifying a genetic cause helps guide the complex decisions...
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay...
Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for...
Testing aids nicotine-use cessation: Paul Jannetto, Ph.D. - Insights
Tobacco use is the leading cause of preventable death in the United States. In this test-specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' nicotine testing benefits patients...
Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D. - Insights
John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.